Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2022 | How novel technologies and machine learning are impacting drug research in amyloidosis

Joost Schymkovitz • 5 Sep 2022
ISA 2022
Amyloidosis Rare Diseases

Joost Schymkovitz, PhD, KU Leuven, Leuven, Belgium, briefly explains how novel technologies and machine learning are impacting drug research and allowing researchers to better understand the structure of amyloid proteins. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

More from Joost Schymkovitz

0:35
Unraveling the tropisms of amyloid deposition through amyloid-protein interactions
Joost Schymkovitz • 5 Sep 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals